# Axon Therapies, Inc.

> Axon Therapies is a clinical-stage medical device company developing SAVM (Splanchnic Ablation for Volume Management), a minimally invasive, implant-free catheter procedure that ablates the greater splanchnic nerve to calm an overactive sympathetic nervous system and rebalance blood volume in patients with heart failure - particularly heart failure with preserved ejection fraction (HFpEF). Incubated by the medtech studio Coridea and backed by leading healthcare investors, the company is advancing its Satera Ablation System through randomized, sham-controlled feasibility trials.

- **Headquarters:** Santa Clara, California, United States
- **Founders:** Zoar Engelman (Co-founder, President & CEO (former Chief Scientific Officer)), Howard Levin (Co-founder & Chief Medical Officer; co-founder of Coridea), Coridea (Founding medtech incubator/studio)
- **Team size:** ~10 employees
- **Products:** Satera Ablation System, SAVM (Splanchnic Ablation for Volume Management), Axon Ablation Catheter
- **Notable:** Raised $32M in an oversubscribed Series A (September 2025) to advance heart failure treatment., Developed a first-in-class splanchnic ablation procedure (SAVM) targeting a root cause of heart failure., Ran REBALANCE-HF, one of the largest randomized, sham-controlled, blinded feasibility device trials in HFpEF to date (116 patients across 18 sites).

## Products & services

- **Satera Ablation System** — An investigational, minimally invasive, implant-free catheter system delivered through the femoral vein to perform targeted ablation of the greater splanchnic nerve. The outpatient procedure typically takes under an hour.
- **SAVM (Splanchnic Ablation for Volume Management)** — The proprietary therapeutic procedure that uses radiofrequency ablation of the right greater splanchnic nerve to calm the overactive sympathetic nervous system and normalize blood volume distribution in heart failure patients.
- **Axon Ablation Catheter** — The catheter component navigated to a target vessel near the right greater splanchnic nerve to deliver targeted ablation therapy that blocks sympathetic nerve signals.

## Achievements

- Raised $32M in an oversubscribed Series A (September 2025) to advance heart failure treatment.
- Developed a first-in-class splanchnic ablation procedure (SAVM) targeting a root cause of heart failure.
- Ran REBALANCE-HF, one of the largest randomized, sham-controlled, blinded feasibility device trials in HFpEF to date (116 patients across 18 sites).
- 12-month feasibility data showing reduced pulmonary capillary wedge pressure (~18 mmHg vs sham), ~17-point KCCQ quality-of-life improvement, and ~49-meter gain in 6-minute walk distance.
- Established a European headquarters (Axon Vascular Europe Ltd) in the UK.
- Presented late-breaking clinical data confirming procedure safety and identifying patients most likely to benefit from SAVM.

## Latest updates

- **2025-09** — Closed $32M oversubscribed Series A co-led by Earlybird Venture Capital and Sante Ventures; co-founder Zoar Engelman appointed CEO.
- **2025-09** — Announced plans to advance two double-blinded randomized feasibility studies for HFpEF and HFrEF and to expand toward pivotal/regulatory milestones.
- **2025** — Established European headquarters, Axon Vascular Europe Ltd, in the UK.

## Links

- Website: https://axontherapies.com
- LinkedIn: http://www.linkedin.com/company/axon-therapies-inc.
- Twitter/X: https://twitter.com/axontherapies

---

Profile page: https://yespress.io/axon-therapies-inc
Published by YesPress — https://yespress.io
Last updated: 2026-07-22